BPC June 7 updates: CYTR data delayed until July. CATB falls on disappointing data. CLCD Phase 3 data due 3Q + updates for ALDX CYTX IMUC RGLS SAGE ZGNX

Jun 08, 2016 No Comments by

Updates to the Company Pipeline Database for June 7, 2016, are as follows. Refer to the FDA Calendar for upcoming catalysts: Ticker Price Drug Indication Stage Summary ALDX 5.75 NS2 Sjögren-Larsson Syndrome (SLS) Phase 2 Phase 2 data due 3Q 2016 CATB 6.85 CAT-2054 Hypercholesterolemia Phase 2a Phase 2a did not meet primary endpoint – June 2016 CLCD 7.16 […]

Daily News Read more

Database updates for ACOR ACRS AEZS CTIX CYTX DCTH EYEG INCY SYN TGTX TRVN ZGNX

Jan 20, 2016 No Comments by

Updates to the Company Pipeline Database from January 19, 2016 are as follows. Refer to the FDA Calendar for upcoming catalysts: Ticker Price Drug Indication Stage Summary ACOR 37.55 Tozadenant Parkinson’s disease Phase 3 Announced January 2016 that it entered into an agreement to acquire Biotie Therapies Corp which is currently in Phase 3 development of Tozadenant for Parkinson’s […]

Daily News Read more

ZGNX FDA Approval + updates for APPY CORT IMGN PCYC RDUS SGYP VCEL VRTX

Jan 31, 2015 No Comments by

Expect updates to be streaming in thick and fast over the next two weeks when most small-mid cap companies report 4Q 2014 results. Latest updates to the Company Pipeline Database for January 28-30, 2015. Refer to the FDA Calendar for upcoming catalysts: Ticker Price Drug Indication Stage Link Text Updated APPY 0.50 Appy1 Acute appendicitis […]

Daily News Read more

EGRX granted tentative FDA Approval. ZGNX to file sNDA by October. RGDO to undergo DSMB review.

Jul 02, 2014 No Comments

Zogenix, Inc. (Nasdaq:ZGNX) announced that they expect to file a supplemental new drug application (sNDA) by October 2014 for a formulation of Zohydro ER Extended-Release Capsules designed to make it more difficult to abuse by injection or nasal administration. Zohydro ER is currently indicated for the management of pain. Eagle Pharmaceuticals, Inc. (Nasdaq:EGRX) announced today that the FDA has granted tentative […]

Read more

AEZS file NDA. IMGN fail Phase 2 trial. ECYT decision due Dec-Jan. ADHD data due Dec. KERX positive data + updates for STEM SGEN PTLA ISIS INSM ZGNX ITMN

Nov 06, 2013 No Comments

Aeterna Zentaris Inc. (NASDAQ: AEZS $1.39) announced that it has submitted a NDA for AEZS-130 for adult growth hormone deficiency (“AGHD”). ImmunoGen, Inc. (Nasdaq: IMGN $13.41) announced that it will discontinue their Phase 2 trail of IMGN901 for SCLC, following the recommendation from the Data Monitoring Committee (DMC) due to a higher rate of infection and […]

Read more

Offering news for ITMN ZGNX TTPH. ZLCS data due 4Q. RPRX to request lift of Proellex clinical hold + MSTX BLRX updates

Nov 04, 2013 No Comments

InterMune, Inc. (NASDAQ: ITMN $14.95) announced that it plans to offer 6,500,000 shares of its common stock in an underwritten public offering. Zogenix, Inc. (Nasdaq:ZGNX $2.54) announced today that it intends to offer $60 million of shares of its common stock in an underwritten public offering. Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH $12.28) also announced it has commenced an underwritten public offering […]

Read more

ZGNX FDA Approval. GILD gets Adcom thumbs up. Offering news for MEIP DVAX CUR + updates for IMGN and SNTS

Oct 26, 2013 No Comments

Zogenix, Inc. (Nasdaq:ZGNX $3.04) announced that the FDA has approved Zohydro ER (hydrocodone bitartrate) extended-release capsules, for the management of pain. Zogenix expects to launch Zohydro ER in approximately four months. Gilead Sciences, Inc. (Nasdaq: GILD $69.68) announced that the Antiviral Drugs Advisory Committee of the FDA voted unanimously (15-0) in favour of sofosbuvir in combination with ribavirin for the treatment […]

Read more

Updates for ALNY ZGNX INSV DNDN OGXI ANAC RPTP NPSP NKTR KERX APPA SRPT THLD OPXA BCRX IMUC INFI

Aug 09, 2013 No Comments

Zogenix, Inc. (Nasdaq:ZGNX $1.52) said it continues to expect that the FDA will reach a decision regarding the Zohyrdo ER New Drug Application(NDA), during the summer of 2013. NPS Pharmaceuticals, Inc. (NASDAQ: NPSP $18.10) said that it expects to submit its Biologic License Application in 4Q 2013 for Natpara for patients with hypoparathyroidism. It also plans to initiate […]

Read more

CELG Approval for REVLIMID + updates for BMRN IDRA ZGNX OPK PBTH RCPT MELA

Jun 05, 2013 No Comments

Celgene Corporation (NASDAQ: CELG) announced the FDA approved the supplemental new drug application (sNDA) for REVLIMID (lenalidomide) for the treatment of patients with mantle cell lymphoma (MCL) whose disease has relapsed or progressed after two prior therapies, one of which included bortezomib. BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced that it has initiated the Phase 3 program (165-301) for PEG-PAL (PEGylated […]

Read more

Pipeline updates for OPK VNDA SNSS SRPT NKTR INSV VICL PBYI ANAC SPPI NPSP IMUC ZGNX + OMER offering

May 10, 2013 No Comments

OPKO Health, Inc. (NYSE: OPK) noted that Phase 3 data of CTAP 101 Capsules for the treatment of Secondary Hyperparathyroidism (SHPT) are due mid-2014, while Phase 3 data from its licensee trial (TESARO, Inc.) of rolapitant for the prevention of chemotherapy induced nausea and vomiting, are expected during 2H 2013. Vanda Pharmaceuticals Inc.(Vanda) (NASDAQ: VNDA) maintained guidance […]

Read more

ASTM stops Phase 3 REVIVE trial. NDA filings for IGXT POZN. BIIB FDA approval + updates for NBIX ZGNX ARRY NAVB CPRX KBIO

Mar 27, 2013 No Comments

Aastrom Biosciences, Inc. (Nasdaq:ASTM) announced that it will stop enrollment and end the Phase 3 REVIVE clinical trial of  ixmyelocel-T in patients with critical limb ischemia (CLI) due to an inability to secure a partner, and challenges with enrollment. The company will  now focus its resources on its Phase 2b trial of ixmyelocel-T, for the treatment […]

Read more